At the news
? BEARISHIMPACT 6/10 8-K filed Jun 2, 2026 at 16:39 ET
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for ARV-806 (KRAS G12D) and then seek an out-licensing partner for further development. The company also furnished an investor presentation for the Jefferies Global Healthcare Conference. Cash runway extends into H2 2028.
- Arvinas is deprioritizing ARV-806, its KRAS G12D program, after completing Phase 1 dose escalation enrollment in Q2 2026.
- The company plans to out-license any further clinical trials (dose expansion or combination) for ARV-806.
- Cash, cash equivalents, and marketable securities as of March 31, 2026 are expected to fund operations into H2 2028.
- An investor presentation was furnished for the Jefferies Global Healthcare Conference on June 3, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access